Soltis Investment Advisors LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD

Soltis Investment Advisors LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 37.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,600 shares of the biopharmaceutical company’s stock after selling 2,113 shares during the period. Soltis Investment Advisors LLC’s holdings in Gilead Sciences were worth $399,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Souders Financial Advisors lifted its position in Gilead Sciences by 28.4% in the second quarter. Souders Financial Advisors now owns 3,484 shares of the biopharmaceutical company’s stock valued at $386,000 after purchasing an additional 771 shares during the last quarter. Achmea Investment Management B.V. raised its holdings in Gilead Sciences by 13.6% during the 2nd quarter. Achmea Investment Management B.V. now owns 455,788 shares of the biopharmaceutical company’s stock valued at $50,533,000 after buying an additional 54,576 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in Gilead Sciences by 43.0% during the 2nd quarter. Golden State Wealth Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 371 shares during the last quarter. Sienna Gestion boosted its position in Gilead Sciences by 10.4% during the 2nd quarter. Sienna Gestion now owns 56,263 shares of the biopharmaceutical company’s stock valued at $5,695,000 after buying an additional 5,294 shares during the period. Finally, Andra AP fonden grew its holdings in Gilead Sciences by 140.0% in the 2nd quarter. Andra AP fonden now owns 577,800 shares of the biopharmaceutical company’s stock worth $64,061,000 after acquiring an additional 337,100 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on GILD shares. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $127.82.

Gilead Sciences Trading Down 3.7%

Shares of NASDAQ GILD opened at $118.84 on Friday. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a 50-day moving average of $116.49 and a 200 day moving average of $112.17. The stock has a market cap of $147.46 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the firm earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s payout ratio is presently 48.99%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the sale, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.